Tjerkaski, Jonathan Jernberg, Tomas Alfredsson, Joakim Erlinge, David James, Stefan Lindahl, Bertil Mohammad, Moman Aladdin Omerovic, Elmir Venetsanos, Dimitrios Szummer, Karolina
...
Published in
European heart journal. Cardiovascular pharmacotherapy
Ticagrelor is associated with a lower risk of ischemic events than clopidogrel. However, it is uncertain whether the benefits of more intensive anti-ischemic therapy outweigh the risks of major bleeding in patients who have a high bleeding risk (HBR). Therefore, this study compared ticagrelor and clopidogrel in myocardial infarction (MI) patients w...
Komócsi, András Merkely, Béla Hadamitzky, Martin Massberg, Steffen Rizas, Konstantinos D Hein-Rothweiler, Ralph Gross, Lisa Trenk, Dietmar Sibbing, Dirk Aradi, Dániel
...
Published in
European heart journal. Cardiovascular pharmacotherapy
Clinical guidelines recommend de-escalation antiplatelet strategies to reduce bleeding risk in acute coronary syndrome (ACS) patients, albeit with a weak recommendation. This substudy of the TROPICAL-ACS trial aimed to determine the impact of body mass on the efficacy of a platelet function testing-guided de-escalation regimen in ACS patients after...
Calvert, Peter Gupta, Dhiraj Lip, Gregory Y H
Published in
European heart journal. Cardiovascular pharmacotherapy
Atrial fibrillation (AF) has a recognized association with not only stroke, but also neurocognitive impairment and both vascular and Alzheimer's dementia. Effective management of AF can reduce the risk of such complications. In this narrative review article, we discuss the pathophysiological links between AF and dementia, as well as the benefits of...
Valgimigli, Marco Aboyans, Victor Angiolillo, Dominick Atar, Dan Capodanno, Davide Halvorsen, Sigrun James, Stefan Jüni, Peter Kunadian, Vijay Landi, Antonio
...
Published in
European heart journal. Cardiovascular pharmacotherapy
Multiple guidelines and consensus papers have addressed the role of antithrombotic strategies in patients with established coronary artery disease (CAD). Since evidence and terminology continue to evolve, the authors undertook a consensus initiative to guide clinicians to select the optimal antithrombotic regimen for each patient. The aim of this d...
Schmidt, Morten Arendt-Nielsen, Lars Hauge, Ellen-Margrethe Sørensen, Henrik Toft Pedersen, Lars
Published in
European heart journal. Cardiovascular pharmacotherapy
To examine the dose dependency of diclofenac's cardiovascular risks. Using Danish health registries and the target trial emulation design, we conducted a series of 300 nationwide cohort studies during 1996-2020, each mimicking the strict design criteria of a clinical trial. Adults eligible for inclusion had no recent non-steroidal anti-inflammatory...
Ye, Xuxiao Huang, Caige Yan, Vincent Ka Chun Kang, Wei Fan, Min Tsang, Gigi Kwan Chi Ho, Clarissa Mung Yee Lip, Gregory Y H Yiu, Kai-Hang Tse, Hung-Fat
...
Published in
European heart journal. Cardiovascular pharmacotherapy
Patients with atrial fibrillation (AF) have a higher risk of ischaemic stroke or systemic embolism, with a greater risk for female patients. This study aims to evaluate the risk of ischaemic stroke or systemic embolism and bleeding following COVID-19 vaccination in patients with AF and the sex differences. Self-controlled case series (SCCS) analysi...
Myasoedova, Veronika A Rimbert, Antoine Camera, Marina Le May, Cedric Capoulade, Romain Cariou, Bertrand Poggio, Paolo
Published in
European heart journal. Cardiovascular pharmacotherapy
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key regulator of plasma low-density lipoprotein cholesterol (LDL-C) concentration, and its inhibition reduces the risk of atherosclerotic cardiovascular disease (ASCVD). We aimed to assess the sex-differential effect of either pharmacological or genetic inhibition of PCSK9 on LDL-C levels. ...
Johansen, Nicklas Järvelä Knop, Filip Krag
Published in
European heart journal. Cardiovascular pharmacotherapy
In type 1 diabetes, average life expectancy is reduced by ˃10 years as compared with outside of diabetes. Residual cardiovascular risk defines high cardiovascular event rate despite modern, guideline-recommended standard of care of established risk factors like hypertension, dyslipidaemia, and glycaemic control, and it adds importantly to these los...
Spirito, Alessandro Kastrati, Adnan Cao, Davide Baber, Usman Sartori, Samantha Angiolillo, Dominick J Briguori, Carlo Cohen, David J Dangas, George Dudek, Dariusz
...
Published in
European heart journal. Cardiovascular pharmacotherapy
The aim of this study was to assess the effect of ticagrelor monotherapy among high-risk patients with anaemia undergoing percutaneous coronary intervention (PCI). In the TWILIGHT (Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention) trial, after 3 months of ticagrelor plus aspirin, high-risk patients were maintained ...
Korjian, Serge Kazmi, Syed Hassan A Chi, Gerald Kalayci, Arzu Lee, Jane J Talib, Usama Wright, Samuel D Duffy, Danielle Kingwell, Bronwyn A Mehran, Roxana
...
Published in
European heart journal. Cardiovascular pharmacotherapy
Despite current standard of care treatment, the period shortly after acute myocardial infarction (AMI) is associated with high residual cardiovascular (CV) risk, with high rates of recurrent AMI and CV death in the first 90 days following the index event. This represents an area of high unmet need that may be potentially addressed by novel therapeu...
